SEC Form 4 · accession 0001209191-19-003443
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander O. Schuth
Officer — COO and Secretary
Period of report
Jan 9, 2019
Accepted (ET)
Jan 11, 2019 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 9, 2019 | S | 2,500 | $20.31 | D | 675,089 | I | See footnote |
| Common StockF4,F3 | Jan 10, 2019 | S | 2,500 | $19.99 | D | 672,589 | I | See footnote |
| Common StockF5,F3 | Jan 11, 2019 | S | 2,500 | $20.80 | D | 670,089 | I | See footnote |
| Common Stock | holding | — | — | — | 15,738 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.94 to $20.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.44 to $20.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.24 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.